Abstract Vascular calcification can occur in nearly all arterial beds and in both the medial and intimal layers. The initiating factors and clinical consequences depend on the underlying disease state and location of the calcification. The best studied manifestation is coronary artery calcification, in part because of the obvious clinical consequences, but also because of CT-based imaging modalities. In the general population, the presence of coronary artery calcification increases cardiovascular risk above that predicted by traditional Framingham risk factors, suggesting the presence of nontraditional risk factors. In patients with chronic kidney disease (CKD), coronary artery calcification is more prevalent and markedly more severe than in the general population. In these CKD patients, nontraditional risk factors such as oxidative stress, advanced glycation end products, and disordered mineral metabolism are also more prevalent and more severe and offer mechanistic insight into the pathogenesis of vascular calcification.
Introduction
Calcium is the most common element in bone, and 99 % of the total body calcium is in bone in the form of a calcium phosphate crystalline structure called hydroxyapatite. Calcium is also found outside of bone in a variety of tissues, broadly termed extraskeletal calcification. In these sites, the calcium can be in multiple forms, including hydroxyapatite, magnesium whitlockite, and amorphous calcium phosphate. Calcification in arteries, or vascular calcification, can lead to cardiovascular morbidity and mortality [1] . While cellular necrosis may lead to calcium deposition within or around vascular smooth muscle cells (VSMCs), over the past 15 years, there has been an increased appreciation that vascular calcification is a cell-mediated process. Indeed, the majority of vascular calcification is thought to be purposely laid down by VSMCs that have de-differentiated into osteoblast/chondrocyte-like cells.
Pathophysiology
Arterial calcification can occur in both intimal and medial layers. In the intima, atherosclerotic disease is characterized by fibrofatty plaque formation and based on autopsy data and animal models. Calcification had been thought to occur late in the disease course. However, using intravascular ultrasound, the atherosclerosis can also be a circumferential lesion (without an obstructed lumen), with calcification earlier in the course of the disease [2] . The medial layer may also be affected, leading to thickening of the medial layer of larger elastic arteries and resulting in arteriosclerosis of smaller elastic arteries classically described as Mönckeberg's calcification, or medial calcinosis [3, 4] . This disease of small vessels is more common in patients with diabetes, renal failure, and advanced aging and is associated with increased all-cause and cardiovascular mortality in diabetic patients without chronic kidney disease (CKD) [5] and in CKD patients with and without diabetes [6] .
The clinical manifestations of vascular calcification depend on the location within the arterial wall and the tissue perfused. Intimal, atherosclerotic calcification can lead to myocardial infarction from stenosis and acute thrombus, or ischemia in both coronary and peripheral arteries. Medial or circumferential calcification can lead to reduced compliance due to arterial stiffening, resulting in an impaired vasodilation during ischemia that in theory could lead to arrhythmias and sudden death. With medial calcification (arteriosclerosis) of the aorta, there will be increased pulse wave velocity, elevated pulse pressure, and systolic hypertension. Lastly, calcification of the arterioles of the skin and other organs can lead to calciphylaxis and ischemic gut [7] . Arterial calcification can be detected by plain radiographs, CT methods (including electron beam CT [EBCT] and multislice [spiral] CT), and ultrasound. Unfortunately, with the exception of intravascular ultrasound, none of these techniques can distinguish intimal from medial calcification. CT-based methods are utilized for clinical research, as they allow for quantitation. The higher the coronary artery calcification score, the greater the risk of cardiovascular mortality is in both the general population [8] and among those with CKD [9] .
Age is the strongest predictor of coronary artery disease [8] , but multiple other clinical risk factors have been implicated in the pathogenesis of arterial calcification. Coronary artery calcification is also more prevalent and more severe among CKD patients than in the general population, and studies in CKD patients offer insight into the pathogenesis. Among patients not yet on dialysis, more than 50 % have coronary artery calcification [10] , whereas 70-90 % of prevalent dialysis patients have significant coronary artery calcification [11, 12] . Histologic studies comparing dialysis patients to non-CKD patients who died of a coronary event showed that dialysis patients had more calcification in the atheromatous plaques, but not more plaque. Dialysis patients also had a thicker medial layer [13] . Studies evaluating distal segments of the coronary arteries found medial calcification adjacent to the internal elastic lamina in dialysis patients [14] and in patients with advanced CKD [15] . We found isolated medial calcification in the absence of intimal calcification in the inferior epigastric artery of patients undergoing a renal transplant [16] . Thus, calcification can occur both in intimal and medial arterial layers and in different vascular beds. In a study of 4,544 patients, the presence of calcification in the thoracic aorta, carotids, and iliac arteries was associated with all-cause mortality, with hazard ratios of 2.1, 1.6, and 1.67, respectively, whereas coronary artery calcification was associated with a hazard ratio of 3.4 for cardiovascular mortality [17] . At the present time, it appears that there may be different initiating factors in different vascular beds and in the intima and media, but a common downstream process of de-differentiation into an osteoblast like phenotype.
The mechanism of arterial calcification is complex, but multiple investigators agree that the first step appears to be de-differentiation or transformation of VSMCs into an osteoblast/chondrocytic phenotype (Fig. 1) . VSMCs originate from a similar mesenchymal stem cell as osteoblasts, the latter occurring with upregulation of the transcription factor core binding factor α-1 (Cbfa-1) now called Runt-related transcription factor 2 (RUNX2) or msh homeobox 2 (MSX-2). These cells then do what a normal osteoblast does: secrete matrix proteins. We have shown that there is increased expression of RUNX2 by in situ hybridization in areas adjacent to calcification of the intima and the medial layer of inferior epigastric artery obtained from hemodialysis patients in association with "bone" matrix proteins [16] . The signals that induce this transformation are multiple and are described in detail below. Once the matrix is laid down, these cells then mineralize the matrix through the secretion of matrix vesicles (MVs) [18] or through apoptosis [19] . Phosphorus and calcium increase the mineralizing potential of these MVs [18, 20••] . The latter may explain why the disease is increased in CKD, in which disturbances of mineral metabolism are common, and why there may be a relationship between bone mineralization and coronary calcification [21] . In both bone and arteries, there are inhibitors of calcification, including matrix gla protein, pyrophosphate, and osteopontin, and circulating inhibitors such as fetuin-A [22] . Thus, calcification is a balance between pro-mineralizing factors that stimulate VSMC dedifferentiation and inhibitors of calcification. For the remainder of this review, we focus on the pro-mineralizing factors.
Risk Factors
Vascular calcification can occur with either atherosclerosis or arteriosclerosis, both of which are increased with socalled "traditional" Framingham risk factors. Thus, many clinical series have tried to find associations with such risk factors as coronary artery or peripheral artery calcification. Everhart et al. [23] showed that risk factors for arterial calcification were impaired vibration, duration of diabetes, and high plasma glucose. Patients with diabetes have increased coronary artery calcification, and the presence of diabetic nephropathy increases this risk [10, 24] . Lehto et al. [5] , in a study of 1,059 patients with type 2 diabetes, demonstrated that medial arterial calcification of peripheral arteries was a strong independent predictor of total cardiovascular mortality and also a significant predictor of future coronary heart disease events, stroke, and amputation [5] . In contrast, dyslipidemia in the form of elevated low-density lipoprotein (LDL) cholesterol does not seem to play a role in the coronary artery calcification in patients with CKD [25] whereas nonhigh-density lipoprotein (HDL) cholesterol, but not LDL cholesterol, was associated with increased coronary artery calcification in asymptomatic adults without CKD [26] . Importantly, a recent meta-analysis demonstrated that statins improve atherosclerotic diseases but have no effect on the reduction of coronary artery calcification [27] . Similarly, hypertension and smoking are not consistently identified risk factors for coronary artery calcification.
Clinically, the presence of calcification by EBCT increases the risk of mortality above that predicted by traditional Framingham risk factors. The presence of coronary calcification increases the area under the curve compared with traditional risk factors (0.84 vs 0.71, respectively; P<0.001) [28] . In patients with CKD, there is a progressive increase in coronary artery calcification with loss of renal function that is independent of traditional risk factors [29] . Multiple studies have demonstrated the added value of coronary artery calcification assessment on risk prediction, including the Multi- (Table 1) .
"Traditional" Risk Factors for Vascular Calcification

Hypertension
Hypertension is associated with vascular remodeling and arteriosclerosis. In clinical studies, hypertension is not a commonly cited risk factor for calcification, perhaps . In contrast, in 5/ 6th nephrectomized rats (a model of CKD), treatment with enalapril improved myocardial hypertrophy and progression of renal disease but had no effect on vascular calcification [37] . In a rat model of arterial calcification induced by intramuscular administration of vitamin D plus oral nicotine, increased calcium content of arteries was associated with increased levels of angiotensin II and aldosterone in the tissue; treatment with captopril or spironolactone reduced the calcification [38] . Thus, the renin-angiotensin and aldosterone pathway appear to play a role in arterial calcification. Whether this is due to the reduction of underlying remodeling (arteriosclerosis) or a direct inhibition of the osteogenic transformation will require additional studies.
Diabetes
Our laboratory examined the calcification and expression of "bone" proteins in the inferior epigastric artery of patients undergoing a renal transplant. Patients with diabetes had increased calcification compared with nondiabetic patients, and there was increased expression in the medial layer of bone matrix proteins in the arteries such as osteopontin, type I collagen, and alkaline phosphatase [39] . In vitro, we have found that VSMC incubated with high glucose led to an increase in the expression of the osteoblast transcription factor RUNX2, BMP-2, and osteocalcin and enhanced calcification in bovine VSMCs. The protein kinase C signaling pathway was involved in this high glucose-induced expression of RUNX2 and bone matrix proteins [39] . Another group found that when fed a high-fat diet, the Ldlr -/-diabetic mice developed hyperglycemia, dyslipidemia, and aortic calcification with concomitant upregulation of aortic BMP2 and Msx2 gene expression [40] . Increased glucose increased the BMP-2/Msx2-Wnt pathway, leading to an osteogenic phenotype in a subset of the myofibroblasts; inhibition of the BMP-2 pathway reduced arterial calcification [41] . Interestingly, the location of BMP-2 and BMP-4 differed in diabetic aortas in that BMP-4 was found in the endothelium and BMP-2 throughout the vascular wall [41] . These results suggest that the increased vascular calcification in diabetes is at least partially due to the direct effects of hyperglycemia on transforming the VSMCs to an osteoblastlike phenotype via multiple mechanisms.
Dyslipidemia
Although clinically, the role of lipids in vascular calcification is unclear, during osteogenic differentiation, calcifying vascular cells (CVCs, clones of VSMCs that readily calcify) accumulate not only minerals but also lipids such as triglycerides [42] . In vitro, HDL inhibits the osteogenic differentiation pathway [42] . In CVCs, stearate, compared with other fatty acids, promoted mineralization, whereas inhibition of acetyl-CoA carboxylase or acetyl-CoA synthetase reduced mineralization [43•]. In these same CVCs, n-3 unsaturated fatty acids play a protective role through a p38-MAPK (mitogen-activated protein kinase) and PPARγ (peroxisome proliferator activated receptor-γ)-dependent mechanism [44] . Finally, oxidized lipids such as oxysterols and oxidized phospholipids illicit pro-calcific effects in vascular cells, as detailed below [45] . Thus, dyslipidemia, rather than elevated LDL cholesterol, appears to be a major causative factor in vascular calcification.
Nontraditional Risk Factors
Inflammation
Inflammation is a known nontraditional risk factor for atherosclerosis and vascular disease in the healthy population and in CKD, and is associated with increased mortality [46, 47] . Both C-reactive protein [48] and inflammatory cytokines [49] are associated with increased coronary artery calcification in patients with CKD. Interestingly, osteogenesis is associated with local inflammation and macrophage [50] . Tumor necrosis factor (TNF)-α can induce mineralization of calcifying vascular cells in vitro [51] , and co-culture of these cells with monocyte/macrophages (the source of most cytokines) can accelerate mineralization [52] . In human VSMC,, the phosphatidylinositol 3-kinase(PI3K)/Akt pathway may inhibit inflammation-induced calcification, perhaps by mediating alkaline phosphatase, which is a "marker" of osteoblast phenotype, but also a potent inhibitor of a naturally occurring inhibitor of calcification, pyrophosphate [53] . Cytokine stimulation of alkaline phosphatase from VSMCs probably plays an important role also in calcification associated with diabetes, as the TNF-α inhibitor infliximab was shown to reduce the osteogenic phenotype of VSMCs and the extent of medial calcification in LDLR -/-diabetic mice without reducing obesity, hypercholesterolemia, and hyperglycemia [40] .
Oxidative Stress
CKD is a state of increased oxidative stress due to impaired antioxidative mechanisms [54] . Elevations in asymmetric dimethylarginine, a naturally occurring inhibitor of nitric oxide (NO) synthase, are associated with increased intimamedial thickness in the carotid arteries, concentric left ventricular hypertrophy, and mortality in dialysis patients [55] . In a rat model of CKD, the antioxidant Tempol inhibited vascular calcification by reducing oxidative stress and inhibiting osteogenic transdifferentiation of VSMCs [56•] . In the general population, there is growing evidence to indicate that there is a correlation between oxidative stress and the development of vascular calcification [57] [58] [59] [60] . Macrophages, endothelial cells, and smooth muscle cells produce reactive oxygen species such as hydrogen peroxide and superoxide anion in response to several stimuli. The free radical NO is generated from the endothelium from -arginine by the enzyme NO synthase and leads to production of hydroxyl or peroxyl radicals. When VSMCs are treated with β-glycerophosphate or uremic serum for 24 h, the production of H 2 O 2 and early expression of NADPH oxidase subunit p22 (phox) are increased. The elevated oxidative stress was associated with increased expression of RUNX2 and alkaline phosphatase and calcification of VSMCs [57] . An important contributor to oxidative stress in atherosclerotic lesions is the formation of hydrogen peroxide from various sources in vascular cells [58] . A study by Byon et al. [60] demonstrated that H 2 O 2 induces a switch of VSMCs from contractile to osteogenic phenotype associated with an increased expression of RUNX2 and calcification in VSMCs. Furthermore, inhibition of H 2 O 2 -activated AKT signaling pathways blocked increased expression of RUNX2 and VSMC calcification [60] . A similar study also demonstrated that advanced oxidation protein products induce vascular calcification by promoting osteoblast differentiation of human VSMCs via the ERK signaling pathway [59] . In a rabbit model of atherogenesis fed high-dose vitamin D, there was increased oxidative stress and aortic valve calcification/stenosis. The latter could be abrogated by the antioxidant lipoic acid [58] . Lipid oxidation products have direct effects on both bone-forming and bone-resorbing cells. Oxidized LDL directly inhibits differentiation of osteoblasts [45] while directly inducing differentiation of osteoclasts [61] . Oxidized lipids also regulate osteoclastogenic cytokines produced by osteoblasts [62] . Thus, oxidative stress may be causative in vascular calcification and may also explain the relationship between increased coronary artery calcification and osteoporosis found in both those with CKD and the general population [63] .
Advanced Glycation End Products
Proteins can be modified indirectly by reactive carbonyl compounds formed by auto-oxidation of carbohydrates and lipids, leading to eventual formation of advanced glycation end products (AGEs). AGEs have been found in arterial and cardiac tissue as well as atherosclerotic lesions in dialysis patients [64] . Circulating AGEs such as pentosidine are elevated in patients on dialysis [65] . AGE-modified elastin and calcification has been found to colocalize in the aortic media of dialysis patients, and binding of mineral to elastin is thought to be an important factor in the pathogenesis of medial calcification [66] . In cultured VSMCs, AGEs can accelerate calcification of microvascular pericytes [67] . AGEs induced the expression of RUNX2 mRNA and alkaline phosphatase activity and calcification [68] . The receptor for AGE (RAGE) is expressed in a variety of cells, including VSMCs [69] , and these AGE-mediated changes in VSMCs were partially attenuated by a neutralizing antibody to RAGE [70] . A study by Suga et al. [71] demonstrated that activation of RAGE inhibited VSMC phenotypic gene expression and induces osteogenic differentiation of VSMCs. This RAGE-mediated effect was via Notch/Msx2 induction in VSMCs. The results suggest that AGEs that accumulate in diabetes could elicit the osteoblastic differentiation of VSMCs, thereby contributing to vascular calcification via the RAGE pathway.
Abnormal Mineral Metabolism
Hyperphosphatemia
Abnormal mineral metabolism has been recognized as a nontraditional risk factor in the development of vascular calcification in CKD patients and is associated with increased mortality in both predialysis and dialysis patients [1, 72] . Hyperphosphatemia is associated with the prevalence and progression of vascular calcification in dialysis patients [73] . Several studies have demonstrated that the use of noncalcium-based as compared with calcium-based phosphate binders attenuated vascular calcification and mortality in dialysis patients [9, 74] . In the general population, phosphorus levels in the upper quartile of the normal range are also associated with increased cardiovascular and all-cause mortality [75] .
In vitro, phosphate increased the calcification of VSMCs in a dose-dependent manner [76] . High phosphate induced the loss of VSMC markers such as smooth muscle (SM) α-actin and SM22α and increased the expression of the osteochondrogenic markers Runx2, osterix, osteopontin, and alkaline phosphatase [77, 78] . We have demonstrated that bovine VSMCs incubated with calcification media (10 mM β-glycerolphosphate as a phosphate donor) generated cellular MVs that have high annexin II and VI content and the ability to mineralize extracellular matrix compared with that from bovine VSMCs incubated without phosphate [18] . The MVs serve as nucleation sites for calcification, similar to the vesicles that bud from osteoblasts and hypertrophic chondrocytes in normal bone formation. Phosphate transport to cells is primarily mediated by sodium-dependent phosphate (NaPi) co-transporters [79] , and treatment with phosphonoformic acid (PFA, a competitive inhibitor of NaPi transport) inhibits phosphate uptake and VSMC osteochondrogenic differentiation [76] . The type III NaPi co-transporter, PiT-1, is highly expressed in VSMC [80] , and the knockdown PiT-1 with siRNA suppressed phosphateinduced calcification and blocked induction of the osteogenic markers Runx2/Cbfa1 and osteopontin [80] . However, our group has shown that bovine VSMCs incubated with pooled uremic sera from dialysis patients had increased calcification above that induced by phosphorus, but only when phosphorus is available [81] . The addition of PFA (inhibitor of NaPi transport) or levamisole (inhibitor of alkaline phosphatase) only partially inhibited uremic serum-induced osteopontin upregulation. The cyclic adenosine monophosphate (cAMP)/ protein kinase A signaling pathway was involved in uremic serum-induced upregulation of RUNX2 and alkaline phosphatase [82] . High phosphate may also regulate matrix mineralization through elastin degradation. A soluble elastin-derived peptide can induce mineralization of human VSMCs in the presence of high phosphorus concentration [83] . Treatment of rat VSMCs with elastin peptide induced the expression of elastin-laminin receptors along with increased expression of osteoblastic transcription factor RUNX2 and alkaline phosphatase [84] . Transforming growth factor (TGF)-β, which is known to upregulate RUNX2 [85] , had synergistic effect on VSMC phenotypic change. In a rat aortic ring model, treatment with high phosphate and warfarin increased matrix metalloproteinase 9 (MMP-9) activity, followed by TGF-β signaling and aortic calcification [86] . We recently demonstrated that MMP-2 and MMP-9 expression and activity are increased with progressive CKD, and blockade of MMP activity can inhibit arterial calcification [87•] . This matrix degradation or alteration may be an initial step in calcification.
Hypercalcemia
There is an association with elevated serum calcium and the development of vascular calcification in the CKD population [72] . In addition, the use of calcium-containing phosphate binders that induce positive calcium balance is associated with increased arterial calcification in the majority of studies [88] . In vitro, calcium alone can increase human VSMC calcification [89] . Furthermore, calcium and phosphorus had synergistic roles in inducing mineralization of VSMCs [90] . In an aorta ring culture model, elevated calcium was more potent than phosphorus to induce VSMC calcification for a given concentration of calcium and phosphorus, called the Ca X P product [91, 92•] . Calcium also stimulates VSMC MV release [90] . We have demonstrated that calcified VSMC-derived cellular MVs are enriched with annexin II and VI, but with little fetuin-A [18] . Furthermore, blockade of annexin calcium channel activity with K201or the L-type calcium channel blocker verapamil significantly inhibits MV activity and the calcification of VSMCs [20••] . Kapustin and colleagues [93] also demonstrated that blockade of intracellular calcium increase can inhibit MV calcification. It is clear that abnormal mineral metabolism contributes to the development of vascular calcification via multiple mechanisms.
FGF23
The hormone fibroblast growth factor 23 (FGF23) is predominantly expressed in osteocytes and is involved in mineral homeostasis by inducing hyperphosphaturia, inhibiting calcitriol synthesis, and inhibiting parathyroid hormone secretion [94] . In the kidney, it exerts its biological functions by binding to the FGF receptor in the presence of the cofactor Klotho [95] . Several studies have demonstrated that FGF23 is associated with coronary artery and aortic vascular calcification in CKD and dialysis patients [96, 97•] . Targeted deletion of FGF23 or Klotho in mice resulted in hyperphosphatemia and vascular calcification [95, 98] . In moderately uremic mice fed high-phosphate diets, elevated serum FGF23 and osteopontin levels, but not serum phosphorus levels, were associated with extensive arterial-medial calcifications [99] . A recent study by Takei et al. [100] has demonstrated that the expression of stanniocalcin 2, a calcium/ phosphate-regulating hormone, is increased and colocalized in calcified lesions of FGF23 or Klotho-null mice. Although the mechanism by which FGF23 affects vascular calcification is not clear at present, these data suggest that another mechanism by which phosphate affects vascular calcification may be through phosphorus-mediated elevation of FGF23 levels.
Conclusions
CKD represents a model of accelerated vascular calcification and provides insight into the pathogenesis of arterial calcification and the importance of nontraditional risk factors.
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